Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241713390 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Paul van der Leest und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology (EA10), University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agena Bioscience, Bio-Rad.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Analysis of circulating tumor DNA (ctDNA) is a potential minimally invasive molecular tool to guide treatment decision-making and disease monitoring. A suitable diagnostic-grade platform is required for the detection of tumor-specific mutations with high sensitivity in the circulating cell-free DNA (ccfDNA) of cancer patients. In this multicenter study, the ccfDNA of 72 patients treated for advanced-stage non-small cell lung cancer (NSCLC) was evaluated using the UltraSEEK® Lung Panel on the MassARRAY® System, covering 73 hotspot mutations in EGFR, KRAS, BRAF, ERBB2, and PIK3CA against mutation-specific droplet digital PCR (ddPCR) and routine tumor tissue NGS. Variant detection accuracy at primary diagnosis and during disease progression, and ctDNA dynamics as a marker of treatment efficacy, were analyzed. A multicenter evaluation using reference material demonstrated an overall detection rate of over 90% for variant allele frequencies (VAFs) > 0.5%, irrespective of ccfDNA input. A comparison of UltraSEEK® and ddPCR analyses revealed a 90% concordance. An 80% concordance between therapeutically targetable mutations detected in tumor tissue NGS and ccfDNA UltraSEEK® analysis at baseline was observed. Nine of 84 (11%) tumor tissue mutations were not covered by UltraSEEK®. A decrease in ctDNA levels at 4–6 weeks after treatment initiation detected with UltraSEEK® correlated with prolonged median PFS (46 vs. 6 weeks; p < 0.05) and OS (145 vs. 30 weeks; p < 0.01). Using plasma-derived ccfDNA, the UltraSEEK® Lung Panel with a mid-density set of the most common predictive markers for NSCLC is an alternative tool to detect mutations both at diagnosis and during disease progression and to monitor treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology (EA10), University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
- German Cancer Research Center (DKFZ)-Hector Cancer Institute, University Medical Center Mannheim, 68167 Mannheim, Germany.
- Division of Personalized Medical Oncology (A420), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
- Department of Personalized Oncology, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
- Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
ORCID-Profile: Paul van der Leest, Melanie Janning, Nicolas Lozano, Darryl Irwin, Pierre-Jean Lamy, T Jeroen N Hiltermann, Harry J M Groen, Klaus Pantel, Léon C van Kempen, Harriet Wikman, Ed Schuuring
Förderung
- Agena Bioscience
- Bio-Rad
Zitieren
APA
Leest, P. V., Janning, M., Rifaela, N., Azpurua, M. L. A., Kropidlowski, J., Loges, S., Lozano, N., Sartori, A., Irwin, D., Lamy, P. J., Hiltermann, T. J. N., Groen, H. J. M., Pantel, K., Kempen, L. C. V., Wikman, H., & Schuuring, E. (2023). Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241713390
Vancouver
Leest PV, Janning M, Rifaela N, Azpurua MLA, Kropidlowski J, Loges S, et al. Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241713390
BibTeX
@article{Leest2023,
author = {Leest, Paul van der and Janning, Melanie and Rifaela, Naomi and Azpurua, Maria L Aguirre and Kropidlowski, Jolanthe and Loges, Sonja and Lozano, Nicolas and Sartori, Alexander and Irwin, Darryl and Lamy, Pierre-Jean and Hiltermann, T Jeroen N and Groen, Harry J M and Pantel, Klaus and Kempen, Léon C van and Wikman, Harriet and Schuuring, Ed},
title = {Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241713390}
}
EUVIMED